(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.23%) $79.17
(-0.64%) $2.17
(-0.26%) $2 316.20
(-0.06%) $27.59
(0.06%) $985.20
(0.09%) $0.930
(0.11%) $10.91
(0.11%) $0.800
(0.34%) $91.75
Quarter results tomorrow
(bmo 2024-05-09)
Expected move: +/- 6.60%
Live Chart Being Loaded With Signals
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India...
Stats | |
---|---|
本日の出来高 | 216 633 |
平均出来高 | 580 080 |
時価総額 | 18.19B |
EPS | INR0 ( 2024-02-14 ) |
次の収益日 | ( INR0 ) 2024-05-09 |
Last Dividend | INR3.00 ( 2021-08-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -5.90 |
ATR14 | INR0.690 (0.14%) |
ボリューム 相関
Solara Active Pharma 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Solara Active Pharma 相関 - 通貨/商品
Solara Active Pharma 財務諸表
Annual | 2022 |
収益: | INR14.44B |
総利益: | INR6.55B (45.37 %) |
EPS: | INR-6.16 |
FY | 2022 |
収益: | INR14.44B |
総利益: | INR6.55B (45.37 %) |
EPS: | INR-6.16 |
FY | 2022 |
収益: | INR12.31B |
総利益: | INR5.33B (43.29 %) |
EPS: | INR-16.22 |
FY | 2021 |
収益: | INR16.17B |
総利益: | INR8.47B (52.40 %) |
EPS: | INR69.00 |
Financial Reports:
No articles found.
Solara Active Pharma Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR5.00 | 2019-08-06 |
Last Dividend | INR3.00 | 2021-08-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | INR14.00 | -- |
Avg. Dividend % Per Year | 0.13% | -- |
Score | 0.73 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 1.729 | |
Div. Directional Score | 0.449 | -- |
Year | Amount | Yield |
---|---|---|
2019 | INR5.00 | 1.62% |
2020 | INR6.00 | 1.41% |
2021 | INR3.00 | 0.25% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSB.NS | No Dividend Player | 2023-07-04 | Sporadic | 14 | 0.77% | |
KCP.NS | Dividend Junior | 2023-08-10 | Annually | 23 | 0.55% | |
EIMCOELECO.NS | Dividend Knight | 2023-06-16 | Annually | 23 | 0.80% | |
AGARIND.NS | Ex Dividend Junior | 2023-09-08 | Annually | 11 | 0.44% | |
SUMICHEM.NS | Dividend Junior | 2023-07-20 | Annually | 5 | 0.17% | |
NATCOPHARM.NS | Dividend Junior | 2023-08-22 | Semi-Annually | 29 | 0.68% | |
HITECHCORP.NS | Dividend Junior | 2023-06-30 | Annually | 17 | 0.30% | |
CANBK.NS | Dividend Junior | 2023-06-14 | Sporadic | 22 | 1.58% | |
RICOAUTO.NS | Dividend Junior | 2023-09-22 | Annually | 22 | 0.54% | |
L&TFH.NS | Dividend Junior | 2023-07-21 | Annually | 12 | 0.77% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.219 | 1.500 | -4.38 | -6.57 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | -0.276 | 1.500 | -4.18 | -6.27 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -1.607 | 1.000 | -1.706 | -1.706 | [3 - 30] |
operatingCashFlowPerShareTTM | 43.40 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 43.40 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.342 | 1.000 | 7.64 | 7.64 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.110 | 1.000 | -4.20 | -4.20 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.832 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -6.08 | 1.000 | -0.715 | 0 | [1 - 100] |
returnOnEquityTTM | -0.276 | 2.50 | -2.69 | -6.27 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 43.40 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 43.40 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.111 | 1.000 | 9.72 | 0 | [0.1 - 0.5] |
Total Score | 1.729 |
Solara Active Pharma
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, central nervous system agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB treatment, phenylalanine reducer, recovery of stroke, tardive dyskinesia, treatment of glaucoma and hyperphosphatemia, tropical anti-infective, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. It operates in the Asia Pacific, Europe, North America, South America, and internationally. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。